Research Papers:

Melanoma patients with additional primary cancers: a single-center retrospective analysis

Florentia Dimitriou, Joanna Mangana, Alessandra Curioni-Fontecedro, Markus Rechsteiner, Patrick Turko, Ralph P. Braun, Reinhard Dummer and Phil F. Cheng

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:3373-3384. https://doi.org/10.18632/oncotarget.26931

Metrics: PDF 1201 views  |   Full Text 2302 views  |   ?  


Florentia Dimitriou1, Joanna Mangana1, Alessandra Curioni-Fontecedro2,4, Markus Rechsteiner3, Patrick Turko1, Ralph P. Braun1,4, Reinhard Dummer1,4,* and Phil F. Cheng1,*

1 Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland

2 Department of Hematology and Oncology, Division of Oncology, University Hospital of Zurich, Zurich, Switzerland

3 Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland

4 Faculty of Medicine, University of Zurich, Zurich, Switzerland

* These authors contributed equally to this work

Correspondence to:

Reinhard Dummer,email: [email protected]
Phil F. Cheng,email: [email protected]

Keywords: melanoma; additional primary tumors; multiple primary tumors; BRAF V600E mutation; papillary thyroid cancer

Received: March 28, 2019     Accepted: April 29, 2019     Published: May 21, 2019


Background: Recent progress in the diagnosis and treatment of primary and metastatic cutaneous melanoma (CM) has led to a significant increase in the patients` expectancy of life. The development of additional primary tumors (APT) other than CM represents an important survival issue.

Results: Of a total of 1764 CM patients, 80 (4.5%) patients developed APT. For tumors diagnosed after CM, there was a 2.7 fold excess risk for APT compared to the swiss german population. A significantly increased risk was noted for female breast (SIR, 2.46), male larynx (SIR, 76.92), male multiple myeloma (SIR, 11.2), male oesophagus (SIR, 10.8) and thyroid on males (SIR, 58.8) and females (SIR, 38.1). All thyroid cancer cases had a common papillary histological subtype and a high rate of BRAFV600E mutation. Melanoma was the primary cause of death in the vast majority of patients.

Methods: We used the cancer registry from the Comprehensive Cancer Center Zurich (CCCZ) and retrospectively analyzed patients with CM and APT between 2008 and 2018. We calculated the risk of APT compared to the swiss german population using the standardized incidence ratio (SIR).

Conclusions: Patients with CM have an increased risk for hematologic and solid APT. Long-term follow-up is indicated.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26931